# COVID-19 Protection After Transplant Pilot Study

> **NCT04969263** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 81 (actual)

## Conditions studied

- Kidney Transplant Recipients

## Interventions

- **BIOLOGICAL:** BNT162b2 vaccine (Pfizer/BioNTech)
- **BIOLOGICAL:** mRNA-1273 vaccine (Moderna)

## Key facts

- **NCT ID:** NCT04969263
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-10
- **Primary completion:** 2022-11-10
- **Final completion:** 2023-03-10
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04969263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04969263, "COVID-19 Protection After Transplant Pilot Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04969263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*